Drug Profile
Research programme: phosphodiesterase IVb inhibitors - Sun Pharmaceutical Industries
Latest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator Ranbaxy Laboratories
- Class
- Mechanism of Action Type 4 cyclic nucleotide phosphodiesterase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Asthma; Chronic obstructive pulmonary disease
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Asthma in India
- 16 Jul 2016 No recent reports of development identified for preclinical development in Chronic-obstructive-pulmonary-disease in India
- 25 Mar 2015 Sun Pharmaceutical Industries acquires Ranbaxy